38096 Federal Register / Vol. 86, No. 135 / Monday, July 19, 2021 / Notices 

or to animal or plant products (select 

agents and toxins). This joint effort 

constitutes the Federal Select Agent 

Program. Due to the continuing 

pandemic and concerns for the safety of 

our workshop attendees and employees, 

DSAT replaced in-person workshops 

with webinars. The purpose of the 

webinars is to provide guidance on 

completing APHIS/CDC Form 2 

(Request to Transfer Select Agents and 

Toxins), APHIS/CDC Form 3 (Report of 

a Release/Loss/Theft), and APHIS/CDC 

Form 4 (Reporting the Identification of 

a Select Agent or Toxin) (APHIS/CDC 

Forms 2–4) for interested individuals. 

Two sessions covering the same agenda 

will be held to provide two 

opportunities for interested individuals 

to participate. 

DATES: The webinars will be held 

October 6, 2021 from 10 a.m. to 12:30 

p.m. (EDT) and November 3, 2021 from 

1:30 p.m. to 4:00 p.m. (EDT). 

Registration instructions are found on 

the website, https://

www.selectagents.gov. 

ADDRESSES: The webinars will be 

conducted from the Centers for Disease 

Control and Prevention, 1600 Clifton 

Road NE, Atlanta, Georgia 30329. 

FOR FURTHER INFORMATION CONTACT: 

CDC: Samuel S. Edwin, Ph.D., Director, 

DSAT, Center for Preparedness and 

Response, CDC, 1600 Clifton Road NE, 

MS H–21–7, Atlanta, Georgia 30329. 

Telephone: (404) 718–2000; email: 

lrsat@cdc.gov. APHIS: Jack Taniewski, 

DVM, Director, DASAT, APHIS, 4700 

River Road, Unit 2, Riverdale, MD 

20737. Telephone: (301) 851–2070; 

email: DASAT@usda.gov. 

SUPPLEMENTARY INFORMATION: The two 

public webinar sessions covering the 

same content, scheduled for 

Wednesday, October 6, 2021 and 

Wednesday, November 3, 2021, are 

opportunities for interested individuals 

to obtain guidance on completing the 

APHIS/CDC Forms 2–4 and reporting 

requirements related to the select agent 

and toxin regulations (7 CFR part 331, 

9 CFR part 121 and 42 CFR part 73). For 

individuals not able to attend the 

webinars, the information will be 

available under the training section at 

http://www.selectagents.gov. 

Representatives from the Federal 

Select Agent Program will be present 

during the webinars followed by 

question and answer session to address 

questions and concerns from the 

webinar participants. 

Participants who want to participate 

in the webinar should complete their 

registration online by September 18, 

2021. The registration instructions are 

located on this website: http://

www.selectagents.gov. 

Dated: July 14, 2021. 

Sandra Cashman, 

Executive Secretary, Centers for Disease 

Control and Prevention. 

[FR Doc. 2021–15305 Filed 7–16–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

In accordance with Section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. 

Name of Committee: Safety and 

Occupational Health Study Section 

(SOHSS), National Institute for 

Occupational Safety and Health 

(NIOSH). 

Dates: October 20–21, 2021. 

Time: 11:00 a.m.–5:00 p.m., EDT. 

Place: Teleconference. 

Agenda: The meeting will convene to 

address matters related to the conduct of 

Study Section business and for the 

study section to consider safety and 

occupational health-related grant 

applications. 

For Further Information Contact: 

Michael Goldcamp, Ph.D., Scientific 

Review Officer, NIOSH, CDC, 1095 

Willowdale Road, Morgantown, WV 

26506; Telephone: (304) 285–5951; 

Email: mgoldcamp@cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2021–15246 Filed 7–16–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–21–21DC] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Centers for 

Disease Control and Prevention (CDC) 

has submitted the information 

collection request titled National 

Syringe Services Program (SSP) 

Evaluation to the Office of Management 

and Budget (OMB) for review and 

approval. CDC previously published a 

‘‘Proposed Data Collection Submitted 

for Public Comment and 

Recommendations’’ notice on February 

25, 2021 to obtain comments from the 

public and affected agencies. CDC 

received three public comments related 

to the previous notice. This notice 

serves to allow an additional 30 days for 

public and affected agency comments. 

CDC will accept all comments for this 

proposed information collection project. 

The Office of Management and Budget 

is particularly interested in comments 

that: 

(a) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(b) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; 

(d) Minimize the burden of the 

collection of information on those who 

are to respond, including, through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and 

(e) Assess information collection 

costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570. 

Comments and recommendations for the 

proposed information collection should 

be sent within 30 days of publication of 

this notice to www.reginfo.gov/public/ 

do/PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 86, No. 135 / Monday, July 19, 2021 / Notices 38097 

for Public Comments’’ or by using the 

search function. Direct written 

comments and/or suggestions regarding 

the items contained in this notice to the 

Attention: CDC Desk Officer, Office of 

Management and Budget, 725 17th 

Street NW, Washington, DC 20503 or by 

fax to (202) 395–5806. Provide written 

comments within 30 days of notice 

publication. 

Proposed Project 

National Syringe Services Program 

Evaluation—New—National Center for 

HIV/AIDS, Viral Hepatitis, STD, and TB 

Prevention (NCHHSTP), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

The primary purpose of the National 

Syringe Services Program (SSP) 

Evaluation is to strengthen and improve 

the capacity of SSPs to conduct regular 

monitoring and evaluation to ensure 

that comprehensive prevention services 

are provided to meet the needs of 

people who inject drugs (PWID). The 

project will include SSPs that are listed 

in a publicly available directory of all 

known SSPs in the United States 

maintained by the North American 

Syringe Exchange Network (NASEN; 

https://nasen.org). SSPs will be sent a 

letter of invitation to participate in a 35- 

minute program survey, called the Dave 

Purchase Memorial Survey. 

Participating programs will have the 

option of completing the survey via 

different modalities to enhance 

feasibility and comfort in completing 

the survey, for example via the Research 

Electronic Data Capture (REDCap) or a 

similarly secure web-based application. 

Other modalities for survey 

administration will include a 

coordinated telephone or 

videoconferencing interview. 

The survey will include questions on 

operational characteristics and services, 

client characteristics and drug use 

patterns, client satisfaction, funding 

resources, community relations, and key 

operational successes and challenges. 

Approximately 600 SSPs will be able to 

participate in the survey. We anticipate 

that approximately 20% of SSPs will 

decline to complete the survey, yielding 

approximately 480 completed surveys 

per year. However, given that this is the 

first survey of SSPs funded by CDC 

during the COVID–19 pandemic, it 

makes it challenging to predict response 

rates. We estimate that it will take 35 

minutes to complete the survey, 

regardless of how the respondent 

chooses to complete it (i.e., selfadministered online or intervieweradministered by phone or 

videoconferencing). SSPs that do not 

respond to the initial survey invitation 

will be given reminders to complete the 

survey over the duration of the survey 

implementation period. The final 

reminder will include a link to a single 

question for SSPs that choose not to 

complete the survey about why they 

declined to complete the survey. Given 

the uncertainties in response rates 

described above, we are requesting 

enough burden hours to allow at least 

80% of SSPs to respond to this question. 

We estimate that it will take two 

minutes to respond to this question. 

The total estimated annual burden 

hours are 296. There are no other costs 

to respondents other than their time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses 

per 

respondent 

Average 

burden per 

response 

(hours) 

All participating SSPs ..................................... Survey Y1 and Survey Y2–3 ......................... 480 1 35/60 

Non-responding SSPs .................................... Non-Response Survey Item ........................... 480 1 2/60 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2021–15226 Filed 7–16–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2021–0070] 

Advisory Committee on Immunization 

Practices (ACIP) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting and request 

for comment. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention (CDC), announces the 

following meeting of the Advisory 

Committee on Immunization Practices 

(ACIP). This meeting is open to the 

public. The meeting will be webcast live 

via the World Wide Web. Time will be 

available for public comment. A notice 

of this ACIP meeting has also been 

posted on CDC’s ACIP website at: http:// 

www.cdc.gov/vaccines/acip/index.html. 

In addition, CDC has sent notice of this 

ACIP meeting by email to those who 

subscribe to receive email updates about 

ACIP. 

DATES: The meeting will be held on July 

22, 2021, from 11:00 a.m. to 4:00 p.m., 

EDT (dates and times subject to change), 

see the ACIP website for updates: http:// 

www.cdc.gov/vaccines/acip/index.html. 

The public may submit written 

comments from July 19, 2021 through 

July 22, 2021. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2021– 

0070 by any of the following methods: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Centers for Disease Control 

and Prevention, 1600 Clifton Road NE, 

MS H24–8, Atlanta, Georgia 30329– 

4027, Attn: July 22, 2021 ACIP Meeting. 

Instructions: All submissions received 

must include the Agency name and 

Docket Number. All relevant comments 

received in conformance with the 

https://www.regulations.gov suitability 

policy will be posted without change to 

https://www.regulations.gov, including 

any personal information provided. For 

access to the docket to read background 

documents or comments received, go to 

https://www.regulations.gov. 

FOR FURTHER INFORMATION CONTACT: 

Stephanie Thomas, ACIP Committee 

Management Specialist, Centers for 

Disease Control and Prevention, 

National Center for Immunization and 

Respiratory Diseases, 1600 Clifton Road 

NE, MS–H24–8, Atlanta, Georgia 30329– 

4027; Telephone: (404) 639–8367; 

Email: ACIP@cdc.gov. 

SUPPLEMENTARY INFORMATION: In 

accordance with 41 CFR 102–3.150(b), 

less than 15 calendar days’ notice is 

being given for this meeting due to the 

exceptional circumstances of the 

COVID–19 pandemic and rapidly 


lotter on DSK11XQN23PROD with NOTICES1